De Novo heart failure with reduced ejection fraction

Heart failure is a serious and common disease, with an estimated prevalence of 1 to 2% in industrialised countries. In recent years, its prevalence has steadily increased worldwide. It represents a major public health problem because of its frequency and its consequences in terms of morbidity and mortality, and because of its considerable economic impact on the healthcare system. It remains a topical issue because of the enormous therapeutic advances made in its management in recent years.The aim of this study was to determine the epidemiological, clinical, therapeutic and evolutionary characteristics of newly diagnosed (de Novo) heart failure with reduced LVEF, and to study the extent to which the management of heart failure complies with international recommendations.